Filing Details
- Accession Number:
- 0001140361-18-005648
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-07 18:09:52
- Reporting Period:
- 2018-02-05
- Accepted Time:
- 2018-02-07 18:09:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219445 | P Brian Mckeon | One Idexx Drive Westbrook ME 04092 | Executive Vp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-05 | 6,602 | $38.80 | 47,040 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-05 | 1,696 | $180.53 | 45,344 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 3,706 | $181.44 | 41,638 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 1,200 | $182.33 | 40,438 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2018-02-05 | 6,602 | $0.00 | 6,602 | $38.80 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-13 | No | 4 | M | Direct |
Footnotes
- Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents the weighted average sales price of the shares sold ranging from a low of $180.01 to a high of $181.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of $181.03 to a high of $182.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of $182.04 to a high of $182.57 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.
Billionaire Hedge Funds
